Anti-HLA antibodies posttransplantation in children: do we know what it means?

Transplant Proc. 2009 Jul-Aug;41(6):2109-10. doi: 10.1016/j.transproceed.2009.06.059.

Abstract

Objective: Anti-HLA antibodies posttransplantation are associated with the appearance of acute and chronic rejection. The goal of this study was to determine the association between the presence of anti-HLA antibodies posttransplantation in children and the clinical outcome.

Patients and methods: We studied the presence and the level of class I and II anti-HLA antibodies by microbead technology (Luminex) in 32 children after kidney transplantation; 87% underwent a first transplantation. Their mean age was 13.9 +/- 2.52 years. When anti-HLA was positive, 60% of children showed an increase in creatinine within the previous 3 months. The statistical analysis was performed with the SPSS 9.0 program.

Results: Only 4/32 children displayed class I anti-HLA antibodies at low levels (5-7.2) and 43% class II anti-HLA antibodies (level: 5-308). We did not observe an association between the presence of antibodies and age, sex, type of donor, immunosuppression, hypertension, proteinuria, time from transplantation, or reason to evaluate antibodies; 37.5% showed good graft function. The presence of anti-HLA antibodies posttransplantation was associated with retransplantations and with the percentage of antibodies by panel-reactive antibodies. There was trend towards an association with a previous acute rejection episode (P = .072); 62.5% of children with C4d-positive biopsies displayed anti-HLA antibodies vs 20% of those who were C4d-negative (P = .088). Graft survival was 100%.

Conclusions: The presence of anti-HLA antibodies posttransplantation was influenced by pretransplantation factors-previous level of anti-HLA antibodies, retransplantation, DR matching- and also by posttransplantation factors, such as the occurrence of an acute rejection episode.

MeSH terms

  • Adolescent
  • Antibodies, Monoclonal / therapeutic use
  • Antilymphocyte Serum / immunology*
  • Autoantibodies / blood*
  • Basiliximab
  • Child
  • Female
  • HLA Antigens / immunology*
  • HLA-D Antigens / immunology
  • Histocompatibility Antigens Class I / immunology
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Kidney Transplantation / adverse effects
  • Kidney Transplantation / immunology*
  • Male
  • Mycophenolic Acid / analogs & derivatives
  • Mycophenolic Acid / therapeutic use
  • Recombinant Fusion Proteins / therapeutic use
  • Reoperation / statistics & numerical data
  • Tacrolimus / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Antilymphocyte Serum
  • Autoantibodies
  • HLA Antigens
  • HLA-D Antigens
  • Histocompatibility Antigens Class I
  • Immunosuppressive Agents
  • Recombinant Fusion Proteins
  • Basiliximab
  • Mycophenolic Acid
  • Tacrolimus